CH505 Envelope Immunogens for CD4 Binding Site Antibody Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of a safe and effective HIV-1 vaccine is a high priority, particularly in addressing the lack of access to anti-retroviral treatment in developing countries.
Innovation Solution
Compositions and methods utilizing CH505 envelope immunogens, including mutated forms and nucleic acids, to induce cross-reactive neutralizing antibodies, employing genetic immunization with DNA and/or RNA, and protein immunogens, combined with adjuvants and carriers, to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HIV-1 vaccine approaches are used, then vaccine development is pursued, but broadly neutralizing antibodies are not induced
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations (G458Y, N197D) into the CH505 envelope immunogen sequence. These parameter modifications in the envelope protein structure enable engagement with CH235 unmutated common ancestors and initiation of CD4 binding site antibodies, transforming the immunogen's ability to induce broadly neutralizing antibodies while maintaining vaccine safety and efficacy
2Duration of action of moving object
If anti-retroviral treatment is made available, then HIV-1 infected patients live longer, but access is limited in developing countries
Solution Approach 1:
The patent creates a vaccine strategy that copies the protective effect of anti-retroviral treatment without requiring the actual treatment drugs. By inducing broadly neutralizing antibodies through the CH505 envelope immunogen with specific mutations, the vaccine replicates the life-extending protective effect of ART in a form that can be deployed in developing countries where antiretroviral drugs are not routinely available
Data Source
AI summary
In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction. In some embodiments, the invention provides mRNA sequences of said HIV-1 immunogens.